Early exposure to pet dogs may lower kids' risk of eczema: Study
New Delhi: Early exposure to pet dogs may lower the risk of developing atopic eczema -- a condition characterised by dry, itchy, and inflamed skin -- among children who are genetically prone to the condition.
Eczema is an itchy skin disorder caused by a combination of genetic and environmental effects, but little is known about how the two interact.
The findings provide new insights into what could cause eczema in children and how environmental factors may influence genetic risk, experts say.
The study did not look at the effect of dog exposure in the treatment of existing eczema, and experts caution that introducing a dog may make symptoms worse in some children.
'We know that genetic make-up affects a child's risk of developing eczema and previous studies have shown that owning a pet dog may be protective, but this is the first study to show how this may occur at a molecular level,' said Sara J. Brown, from the University of Edinburgh.
'More work is needed, but our findings mean we have a chance to intervene in the rise of allergic disease, to protect future generations,' she added.
For the research published in Allergy, the team analysed data from 16 European studies to test for interactions between the 24 most significant eczema-associated genetic variants and 18 early-life environmental factors.
They applied their findings to an additional 10 studies and used lab modelling tests to assess their results.
The first analysis (including 25,339 individuals) showed suggestive evidence for interaction between seven environmental factors (antibiotic use, cat ownership, dog ownership, breastfeeding, elder sibling, smoking, and washing practices) and at least one established genetic variant for eczema, with 14 interactions in total.
In the additional analysis (254,532 individuals), dog exposure interacted with a particular genetic risk variant on chromosome 5, near the gene that codes for the interleukin-7 receptor, a protein involved in immune cell function.
Lab modelling tests showed that this variant affects the expression of interleukin-7 receptors in human skin cells and that dog exposure modifies the genetic effect of this variant on the development of eczema, essentially providing a protective effect by suppressing skin inflammation.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
8 hours ago
- Indian Express
Private lunar lander from Japan crashes into moon in failed mission
A private lunar lander from Japan crashed while attempting a touchdown Friday, the latest casualty in the commercial rush to the moon. The Tokyo-based company ispace declared the mission a failure several hours after communication was lost with the lander. Flight controllers scrambled to gain contact, but were met with only silence and said they were concluding the mission. Communications ceased less than two minutes before the spacecraft's scheduled landing on the moon with a mini rover. Until then, the descent from lunar orbit seemed to be going well. CEO and founder Takeshi Hakamada apologized to everyone who contributed to the mission, the second lunar strikeout for space. Two years ago, the company's first moonshot ended in a crash landing, giving rise to the name 'Resilience' for its successor lander. Resilience carried a rover with a shovel to gather lunar dirt as well as a Swedish artist's toy-size red house for placement on the moon's dusty surface. Company officials said it was too soon to know whether the same problem doomed both missions. 'This is the second time that we were not able to land. So we really have to take it very seriously,' Hakamada told reporters. He stressed that the company would press ahead with more lunar missions. A preliminary analysis indicates the laser system for measuring the altitude did not work as planned, and the lander descended too fast, officials said. 'Based on these circumstances, it is currently assumed that the lander likely performed a hard landing on the lunar surface,' the company said in a written statement. Long the province of governments, the moon became a target of private outfits in 2019, with more flops than wins along the way. Launched in January from Florida on a long, roundabout journey, Resilience entered lunar orbit last month. It shared a SpaceX ride with Firefly Aerospace's Blue Ghost, which reached the moon faster and became the first private entity to successfully land there in March. Another US company, Intuitive Machines, arrived at the moon a few days after Firefly. But the tall, spindly lander face-planted in a crater near the moon's south pole and was declared dead within hours. Resilience was targeting the top of the moon, a less treacherous place than the shadowy bottom. The ispace team chose a flat area with few boulders in Mare Frigoris or Sea of Cold, a long and narrow region full of craters and ancient lava flows that stretches across the near side's northern tier. Plans had called for the 2.3-metre resilience to beam back pictures within hours and for the lander to lower the piggybacking rover onto the lunar surface this weekend. Made of carbon fiber-reinforced plastic with four wheels, ispace's European-built rover — named Tenacious — sported a high-definition camera to scout out the area and a shovel to scoop up some lunar dirt for NASA. The rover, weighing just 5 kilograms, was going to stick close to the lander, going in circles at a speed of less than one inch a couple centimeters per second. It was capable of venturing up to two-thirds of 1 kilometer from the lander and should be operational throughout the two-week mission, the period of daylight. Besides science and tech experiments, there was an artistic touch. The rover held a tiny, Swedish-style red cottage with white trim and a green door, dubbed the Moonhouse by creator Mikael Genberg, for placement on the lunar surface. Minutes before the attempted landing, Hakamada assured everyone that ispace had learned from its first failed mission. 'Engineers did everything they possibly could' to ensure success this time, he said. He considered the latest moonshot 'merely a steppingstone' to its bigger lander launching by 2027 with NASA involvement. Ispace, like other businesses, does not have 'infinite funds' and cannot afford repeated failures, Jeremy Fix, chief engineer for ispace's US subsidiary, said at a conference last month. While not divulging the cost of the current mission, company officials said it's less than the first one which exceeded $100 million. Two other US companies are aiming for moon landings by year's end: Jeff Bezos' Blue Origin and Astrobotic Technology. Astrobotic's first lunar lander missed the moon altogether in 2024 and came crashing back through Earth's atmosphere. For decades, governments competed to get to the moon. Only five countries have pulled off successful robotic lunar landings: Russia, the US, China, India and Japan. Of those, only the U.S. has landed people on the moon: 12 NASA astronauts from 1969 through 1972. NASA expects to send four astronauts around the moon next year. That would be followed a year or more later by the first lunar landing by a crew in more than a half-century, with SpaceX's Starship providing the lift from lunar orbit all the way down to the surface. China also has moon landing plans for its own astronauts by 2030.
NDTV
18 hours ago
- NDTV
UK Warns Women About 'Skinny Jabs' If Trying To Get Pregnant
London: The UK's medicine regulator warned on Thursday against taking "skinny jabs" for weight loss if trying to get pregnant or while breastfeeding because of their unknown effects on babies. The Medicines and Healthcare products Regulatory Agency (MHRA) said popular jabs like Ozempic and Wegovy "must not be taken during pregnancy, while trying to get pregnant, or during breastfeeding". It urged women to use "effective contraception while taking these medicines and, in some cases, for up to two months between stopping the medicine and trying to get pregnant". "Anyone who gets pregnant while using them should speak to their healthcare professional and stop the medicine as soon as possible... because there is not enough safety data to know whether taking the medicine could cause harm to the baby," it added. Rebecca Reynolds, a professor of metabolic medicine at the University of Edinburgh, said there was "hardly any available data from human studies" to know if the weight loss drugs were safe in pregnancy. "The data from animal studies suggests the potential for harm with low birthweight and skeletal abnormalities, though more evidence is needed to assess if there are risks of taking these drugs in humans," she added. The MHRA also warned about the impact of another weight-loss and diabetes injection, Mounjaro, on the effectiveness of oral contraception for people who are overweight. "Therefore, those taking Mounjaro who are overweight and are using an oral form of contraception are advised to also use a non-oral form of contraception," it said. Ying Cheong, a consultant in reproductive medicine at the University of Southampton, called the MHRA's advice "both timely and necessary".
The Hindu
20 hours ago
- The Hindu
Europe suffers its largest diphtheria outbreak in 70 years
The largest diphtheria outbreak to strike Western Europe in 70 years has been affecting vulnerable people such as migrants and the homeless since 2022, new research said Wednesday. Diphtheria is a highly contagious bacterial infection that can attack the respiratory tract and spread throughout the body, causing a sore throat, fever and other symptoms. For unvaccinated people, it can be fatal in around 30 percent of cases, and is deadlier for children, according to the World Health Organization. In 2022, there was an unusual surge in the bacteria that causes diphtheria -- Corynebacterium diphtheriae -- in several European countries, particularly among recently arrived migrants, according to a study in the New England Journal of Medicine. That year 362 cases were recorded by the European Centre for Disease Prevention and Control. Contact tracing and screening helped tamp down the outbreak, but rare infections have continued to be recorded, the researchers said. A total of 536 cases, including three deaths, have been recorded across Europe since the start of 2022. Patient samples from 10 countries showed that 98 percent of the cases were in males with an average age of 18. Almost all had recently migrated. "The outbreak, which mainly affected migrants from Afghanistan and Syria, was not the result of people being infected in their countries of origin, but during their migration journeys or in their places of accommodation in European countries," said a joint statement from France's public health agency and the Pasteur Institute. The genetic similarities between the strains seen in people from different countries suggests that there was a "recent point of contact, outside the country of origin" at the source of the outbreak, the statement added. The exact areas affected by the outbreak remains unclear. But a genetic link between the 2022 strain and the one detected in Germany this year indicates that "the bacteria continues to circulate quietly in Western Europe," the statement said. Vaccination is very effective at fending off diphtheria, and the researchers emphasised the importance of immunisation programmes for the general public. They also called for European nations to do more to ensure their most vulnerable people avoid contracting the disease. That included raising awareness of the symptoms among doctors and those in contact with migrants and the homeless, as well as increasing access to vaccines and antibiotic drugs.
